WAVE Life Sciences (WVE) Stock Price, News & Analysis

Company Overview

WAVE Life Sciences Ltd. is a clinical-stage biotechnology company developing RNA medicines for genetic and other serious diseases. The company uses its proprietary oligonucleotide and RNA-editing technologies to target disease-causing genetic instructions, with the goal of selectively correcting, reducing, or modifying RNA activity.

Its development programs have included investigational therapies for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease. WAVE’s pipeline has featured RNA-editing candidates designed to make precise changes to RNA, as well as stereopure oligonucleotides intended to improve the activity and tolerability of RNA-based medicines. These candidates remain subject to clinical and regulatory evaluation.

Founded in 2012, WAVE Life Sciences is headquartered in Lexington, Massachusetts, and has maintained operations in Singapore, supporting its research and development activities. The company’s chief executive officer is Paul Bolno, who has led WAVE since 2019. WAVE’s work is focused primarily on advancing therapies for patients with genetically driven diseases in global clinical and research settings.

Key Stats

• Today's Range: $3.04 to $3.13
• 50-Day Range: $3.14 to $6.10
• 52-Week Range: $3.04 to $21.73
• Volume: 2.82 million shs
• Average Volume: 3.76 million shs
• Market Capitalization: $608.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.65
• Consensus Rating: Moderate Buy

WAVE Life Sciences Stock Analysis - MarketRank™

WAVE Life Sciences scored higher than 58% of companies evaluated by MarketBeat, and ranked 554th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

WAVE Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 15 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

WAVE Life Sciences has a consensus price target of $21.65, representing about 600.6% upside from its current price of $3.09.

Amount of Analyst Coverage

WAVE Life Sciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for WAVE Life Sciences are expected to decrease in the coming year, from ($1.12) to ($1.26) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of WAVE Life Sciences is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of WAVE Life Sciences is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

WAVE Life Sciences has a P/B Ratio of 1.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.44% of the float of WAVE Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

WAVE Life Sciences has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in WAVE Life Sciences has recently increased by 5.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

WAVE Life Sciences does not currently pay a dividend.

Dividend Growth

WAVE Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.16

News Sentiment

WAVE Life Sciences has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for WAVE Life Sciences this week, compared to 6 articles on an average week.

Search Interest

Only 3 people have searched for WVE on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

7 people have added WAVE Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, WAVE Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $132,476.00 in company stock.

Percentage Held by Insiders

24.30% of the stock of WAVE Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

89.73% of the stock of WAVE Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/14/2026
• Chardan's 10th Annual Healthcare Conference: 10/20/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:WVE
• CIK: 1631574
• Web: www.wavelifesciences.com
• Phone: (656) 236-3388
• Fax: 617-949-2901
• Employees: 317
• Year Founded: 2012

Price Target and Rating

• Average Price Target for WAVE Life Sciences: $21.65
• High Price Target: $43.00
• Low Price Target: $10.00
• Potential Upside/Downside: +600.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$204.38 million
• Net Margins: -309.73%
• Pretax Margin: -309.73%
• Return on Equity: -50.36%
• Return on Assets: -40.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.99
• Quick Ratio: 9.99

Sales & Book Value

• Annual Sales: $42.73 million
• Price / Sales: 14.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.10 per share
• Price / Book: 1.00

Miscellaneous

• Outstanding Shares: 197,050,000
• Free Float: 149,165,000
• Market Cap: $608.88 million
• Optionable: Optionable
• Beta: -1.43